Clinical benefit of midodrine hydrochloride in symptomatic orthostatic hypotension: a phase 4, double-blind, placebo-controlled, randomized, tilt-table study
William Smith, Hong Wan, David Much, Antoine G Robinson, Patrick Martin, William Smith, Hong Wan, David Much, Antoine G Robinson, Patrick Martin
Abstract
Objective: Midodrine hydrochloride is a short-acting pressor agent that raises blood pressure in the upright position in patients with orthostatic hypotension. The US Food and Drug Administration's Subpart H approval, under which midodrine was initially approved, requires post-marketing studies to confirm midodrine's clinical benefit in this indication. The purpose of this study was to evaluate the clinical benefit of midodrine with regard to symptom response.
Methods: This was a double-blind, placebo-controlled, randomized, crossover, multicenter study (NCT01518946). Following screening, patients aged ≥18 years with severe symptomatic orthostatic hypotension and on a stable dose of midodrine for at least 3 months were randomized to treatment with either their previous midodrine dose or placebo on day 1 and the respective alternate treatment on day 2. The primary endpoint measured time to syncopal symptoms or near-syncope using a 45-min tilt-table test at 1 h post-dose.
Results: Thirty-three patients were screened for inclusion: 19 received at least one dose of midodrine and had at least one post-dose measurement of the primary endpoint. The least-squares mean time to syncopal symptoms or near-syncope after tilt-table initiation (mean ± standard error) was 1626.6 ± 186.8 s for midodrine and 1105.6 ± 186.8 s for placebo (difference, 521.0 s; 95 % confidence interval 124.2-971.7 s; p = 0.0131). There were 15 adverse events in 10 patients; all of these were mild or moderate in severity, with none considered by the investigators to be related to midodrine.
Interpretation: Midodrine is a well-tolerated and clinically effective treatment for symptomatic orthostatic hypotension.
Keywords: Clinical trial; Midodrine; Orthostatic hypotension.
Figures
References
- Arnold AC, Shibao C. Current concepts in orthostatic hypotension management. Curr Hypertens Rep. 2013;15(4):304–312. doi: 10.1007/s11906-013-0362-3.
- National Institute for Health and Care Excellence (2013) ESUOM5: postural hypotension in adults: midodrine. . Accessed 18 Nov 2014
- Schirger A, et al. Midodrine. A new agent in the management of idiopathic orthostatic hypotension and Shy-Drager syndrome. Mayo Clin Proc. 1981;56(7):429–433.
- Lahrmann H, et al. EFNS guidelines on the diagnosis and management of orthostatic hypotension. Eur J Neurol. 2006;13(9):930–936. doi: 10.1111/j.1468-1331.2006.01512.x.
- Lundbeck LLC (2014) Northera® (droxidopa). Summary of product characteristics. . Accessed 27 Nov 2015
- McTavish D, Goa KL. Midodrine. A review of its pharmacological properties and therapeutic use in orthostatic hypotension and secondary hypotensive disorders. Drugs. 1989;38(5):757–777. doi: 10.2165/00003495-198938050-00004.
- Wright RA, et al. A double-blind, dose-response study of midodrine in neurogenic orthostatic hypotension. Neurology. 1998;51(1):120–124. doi: 10.1212/WNL.51.1.120.
- Kaufmann H, et al. Treatment of orthostatic hypotension due to autonomic failure with a peripheral alpha-adrenergic agonist (midodrine) Neurology. 1988;38(6):951–956. doi: 10.1212/WNL.38.6.951.
- Kratz H. Treatment of hypotensive circular dysregulation using Gutron in practice. Wien Med Wochenschr. 1975;125(12):189–192.
- Lacbnit VK. Treatment of hypotension in general practice with Gutron. Wien Med Wochenschr. 1975;125(25–27):428–431.
- Jankovic J, et al. Neurogenic orthostatic hypotension: a double-blind, placebo-controlled study with midodrine. Am J Med. 1993;95(1):38–48. doi: 10.1016/0002-9343(93)90230-M.
- Low PA, et al. Efficacy of midodrine vs placebo in neurogenic orthostatic hypotension. A randomized, double-blind multicenter study. Midodrine Study Group. JAMA. 1997;277(13):1046–1051. doi: 10.1001/jama.1997.03540370036033.
- Doyle JF, et al. Midodrine: use and current status in the treatment of hypotension. Br J Cardiol. 2012;19:34–37. doi: 10.5837/bjc.2012.007.
- Kaufmann H, et al. The Orthostatic Hypotension Questionnaire (OHQ): validation of a novel symptom assessment scale. Clin Auton Res. 2012;22(2):79–90. doi: 10.1007/s10286-011-0146-2.
- Koch GG. The use of non-parametric methods in the statistical analysis of the two-period change-over design. Biometrics. 1972;28(2):577–584. doi: 10.2307/2556170.
- Ricci F, De Caterina R, Fedorowski A. Orthostatic hypotension: epidemiology, prognosis, and treatment. J Am Coll Cardiol. 2015;66(7):848–860. doi: 10.1016/j.jacc.2015.06.1084.
- Perlmuter LC, et al. A review of the etiology, associated comorbidities, and treatment of orthostatic hypotension. Am J Ther. 2013;20(3):279–291. doi: 10.1097/MJT.0b013e31828bfb7f.
- Low PA, Tomalia VA. Orthostatic hypotension: mechanisms, causes, management. J Clin Neurol. 2015;11(3):220–226. doi: 10.3988/jcn.2015.11.3.220.
- Fedorowski A, et al. Orthostatic hypotension predicts incidence of heart failure: the Malmo preventive project. Am J Hypertens. 2010;23(11):1209–1215. doi: 10.1038/ajh.2010.150.
- Rose KM, et al. Orthostatic hypotension predicts mortality in middle-aged adults: the atherosclerosis risk in communities (ARIC) study. Circulation. 2006;114(7):630–636. doi: 10.1161/CIRCULATIONAHA.105.598722.
- Fedorowski A, et al. Orthostatic hypotension predicts all-cause mortality and coronary events in middle-aged individuals (The Malmo Preventive Project) Eur Heart J. 2010;31(1):85–91. doi: 10.1093/eurheartj/ehp329.
- Ward CR, et al. Midodrine: a role in the management of neurocardiogenic syncope. Heart. 1998;79(1):45–49. doi: 10.1136/hrt.79.1.45.
- Rutan GH, et al. Orthostatic hypotension in older adults. The Cardiovascular Health Study. CHS Collaborative Research Group. Hypertension. 1992;19(6 Pt 1):508–519. doi: 10.1161/01.HYP.19.6.508.
- Gangavati A, et al. Hypertension, orthostatic hypotension, and the risk of falls in a community-dwelling elderly population: the maintenance of balance, independent living, intellect, and zest in the elderly of Boston study. J Am Geriatr Soc. 2011;59(3):383–389. doi: 10.1111/j.1532-5415.2011.03317.x.
- Mehrabian S, et al. Relationship between orthostatic hypotension and cognitive impairment in the elderly. J Neurol Sci. 2010;299(1–2):45–48. doi: 10.1016/j.jns.2010.08.056.
- Schatz IJ, Miller MJ, Frame B. Corticosteroids in the management of orthostatic hypotension. Cardiology. 1976;61(suppl 1):280–289. doi: 10.1159/000169821.
- Logan IC, Witham MD. Efficacy of treatments for orthostatic hypotension: a systematic review. Age Ageing. 2012;41(5):587–594. doi: 10.1093/ageing/afs061.
Source: PubMed